Hospitalization rates in patients switched from oral anti-psychotics to aripiprazole once-monthly: Final efficacy analysis

Journal of Medical Economics

Volumn 18, Issue 2, 2015, Pages 145-154

  Kane, John M ^a   Zhao, Cathy ^b   Johnson, Brian R ^b   Baker, Ross A ^b   Eramo, Anna ^c   McQuade, Robert D ^b   Duca, Anna R ^b   Sanchez, Raymond ^b   Peters Strickland, Timothy ^b  

^a ZUCKER HILLSIDE HOSPITAL   (United States)

^b OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

^c LUNDBECK RESEARCH USA   (United States)

Author keywords

Anti psychotic agent; Aripiprazole once monthly; Hospitalization; Long acting injectable; Schizophrenia

Indexed keywords

ARIPIPRAZOLE; NEUROLEPTIC AGENT; DELAYED RELEASE FORMULATION;

ADULT; AGED; AKATHISIA; ANXIETY DISORDER; ARTICLE; AUDITORY HALLUCINATION; BACKACHE; CONTROLLED STUDY; DEPRESSION; DIZZINESS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HEADACHE; HOSPITALIZATION; HUMAN; INJECTION SITE PAIN; INSOMNIA; MALE; MENTAL HOSPITAL; MULTICENTER STUDY; NAUSEA; PARANOID SCHIZOPHRENIA; PHASE 3 CLINICAL TRIAL; PSYCHOSIS; SCHIZOPHRENIA; SOMNOLENCE; SUICIDAL IDEATION; TOOTH PAIN; TREATMENT OUTCOME; TREMOR; CLINICAL TRIAL; DELAYED RELEASE FORMULATION; ECONOMICS; INTRAMUSCULAR DRUG ADMINISTRATION; MIDDLE AGED; NORTH AMERICA; RETROSPECTIVE STUDY; SOCIOECONOMICS; STATISTICS AND NUMERICAL DATA;

ADULT; ANTIPSYCHOTIC AGENTS; ARIPIPRAZOLE; DELAYED-ACTION PREPARATIONS; FEMALE; HOSPITALIZATION; HUMANS; INJECTIONS, INTRAMUSCULAR; MALE; MIDDLE AGED; NORTH AMERICA; RETROSPECTIVE STUDIES; SCHIZOPHRENIA; SOCIOECONOMIC FACTORS;

EID: 84923194301     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2014.979936     Document Type: Article

References (36)

1. World Health Organization. Schizophrenia. Geneva, Switzerland: World Health Organization, 2014. http://www.who.int/mental-health/management/schizophrenia/en/. Accessed February 10, 2014
2. Wu EQ, Birnbaum HG, Shi L, et al. The economic burden of schizophrenia in the United States in 2002. J Clin Psychiatry 2005;66:1122-9
3. Gustavsson A, Svensson M, Jacobi F, et al. Cost of disorders of the brain in Europe 2010. Eur Neuropsychopharmacol 2011;21:718-79
4. Hasan A, Falkai P, Wobrock T, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. World J Biol Psychiatry 2013;14:2-44
5. Novick D, Haro JM, Suarez D, et al. Predictors and clinical consequences of non-adherence with antipsychotic medication in the outpatient treatment of schizophrenia. Psychiatry Res 2010;176:109-13
6. Offord S, Lin J, Mirski D, et al. Impact of early nonadherence to oral anti-psychotics on clinical and economic outcomes among patients with schizophrenia. Adv Ther 2013;30:286-97
7. Gilmer TP, Dolder CR, Lacro JP, et al. Adherence to treatment with antipsych-otic medication and health care costs among Medicaid beneficiaries with schizophrenia. Am J Psychiatry 2004;161:692-9
8. Weiden PJ, Kozma C, Grogg A, et al. Partial compliance and risk of rehos-pitalization among California Medicaid patients with schizophrenia. Psychiatr Serv 2004;55:886-91
9. Velligan DI, Weiden PJ, Sajatovic M, et al. The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness. J Clin Psychiatry 2009;70:1-46; quiz 47-8
10. Fleischhacker WW, Sanchez R, Perry PP, et al. Aripiprazole once-monthly for treatment of schizophrenia: a double-blind, randomised, non-inferiority study. Br J Psychiatry 2014;205:135-44
11. Chue P, Eerdekens M, Augustyns I, et al. Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets. Eur Neuropsychopharmacol 2005;15:111-7
12. Detke HC, Zhao F, Garhyan P, et al. Dose correspondence between olanza-pine long-acting injection and oral olanzapine: recommendations for switching. Int Clin Psychopharmacol 2011;26:35-42
13. Leucht C, Heres S, Kane JM, et al. Oral versus depot antipsychotic drugs for schizophrenia-a critical systematic review and meta-analysis of randomised long-term trials. Schizophr Res 2011;127:83-92
14. Kishimoto T, Robenzadeh A, Leucht C, et al. Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials. Schizophr Bull 2014;40:192-213
15. Kishimoto T, Nitta M, Borenstein M, et al. Long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies. J Clin Psychiatry 2013;74:957-65
16. Kirson NY, Weiden PJ, Yermakov S, et al. Efficacy and effectiveness of depot versus oral antipsychotics in schizophrenia: synthesizing results across different research designs. J Clin Psychiatry 2013;74:568-75
17. Asseburg C, Willis M, Lothgren M, et al. Hospitalisation utilisation and costs in schizophrenia patients in Finland before and after initiation of risperidone long-acting injection. Schizophr Res Treatment 2012;2012:791468
18. Tiihonen J, Haukka J, Taylor M, et al. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am J Psychiatry 2011;168:603-9
19. Keith S. Advances in psychotropic formulations. Prog Neuropsychopharmacol Biol Psychiatry 2006;30:996-1008
20. Burris KD, Molski TF, Xu C, et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 2002;302:381-9.
21. Abilify Maintena® US (aripiprazole). Full Prescribing Information. Tokyo, Japan: Otsuka Pharmaceutical Co., Ltd., 2013
22. Abilify Maintena® EU (aripiprazole). Full Prescribing Information. Wexham, UK: Otsuka Pharmaceutical Europe Ltd., 2013
23. TM CAN (aripiprazole). Full Prescribing Information. Saint-Laurent, QC, Canada: Otsuka Canada Pharmaceutical Inc., 2014
24. Kane J, Sanchez R, Perry P, et al. Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2012;73:617-24
25. Kane JM, Sanchez R, Zhao J, et al. Hospitalisation rates in patients switched from oral anti-psychotics to aripiprazole once-monthly for the management of schizophrenia. J Med Econ 2013;16:917-25
26. Kane JM, Peters-Strickland T, Baker RA, et al. Aripiprazole once-monthly in the acute treatment of schizophrenia: findings from a 12-week, randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2014;August 19 [Epub ahead of print]
27. Bera R, Offord S, Zubek D, et al. Impact on healthcare resource usage and costs among Medicaid-insured schizophrenia patients after initiation of treatment with long-acting injectable antipsychotics. J Med Econ 2013;16:522-8
28. Fuller M, Shermock K, Russo P, et al. Hospitalisation and resource utilisation in patients with schizophrenia following initiation of risperidone long-acting therapy in the Veterans Affairs Healthcare System. J Med Econ 2009;12:317-24
29. Peng X, Ascher-Svanum H, Faries D, et al. Decline in hospitalization risk and health care cost after initiation of depot antipsychotics in the treatment of schizophrenia. Clinicoecon Outcomes Res 2011;3:9-14
30. Taylor D, Olofinjana O. Long-acting paliperidone palmitate-interim results of an observational study of its effect on hospitalization. Int Clin Psychopharmacol 2014;29:229-34
31. Lin J, Wong B, Offord S, et al. Healthcare cost reductions associated with the use of LAI formulations of antipsychotic medications versus oral among patients with schizophrenia. J Behav Health Serv Res 2013;40:355-66
32. Lafeuille MH, Laliberte-Auger F, Lefebvre P, et al. Impact of atypical long-acting injectable versus oral antipsychotics on rehospitalization rates and emergency room visits among relapsed schizophrenia patients: a retrospective database analysis. BMC Psychiatry 2013;13:221
33. Godman B, De Bruyn K, Miranda J, et al. Generic atypical antipsychotic drugs in Belgium: their influence and implications. J Comp Eff Res 2013;2:551-61
34. Marder SR, McQuade RD, Stock E, et al. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr Res 2003;61:123-36
35. Godman B, Petzold M, Bennett K, et al. Can authorities appreciably enhance the prescribing of oral generic risperidone to conserve resources? Findings from across Europe and their implications. BMC Med 2014;12:98
36. Lehman AF, Lieberman JA, Dixon LB, et al. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry 2004;161:1-56